Effect of Losartan in Reducing Microalbuminuria on Diabetic Patient

Mst. Shakila Parvin¹, Monjila Khatun², Sabiha Yeasmin Moni³, Md. Awal Hossain⁴

¹ Associate Professor, Department of Pharmacology &Therapeutics, Rajshahi Medical College, Rajshahi, Bangladesh.
² Assistant Professor, Department of Pharmacology &Therapeutics, Rajshahi Medical College, Rajshahi, Bangladesh.
³ Professor, Department of Pharmacology &Therapeutics, Rajshahi Medical College, Rajshahi, Bangladesh.
⁴ Professor, Department of Public Administration, University of Rajshahi, Bangladesh

Abstract

Background: Diabetic nephropathy is the chronic loss of kidney function occurring in those with diabetes mellitus and is a leading cause of chronic kidney disease and end-stage renal disease globally. Microalbumuria is an important marker of diabetic nephropathy.
Objective: The present study was undertaken to evaluate the Microalbuminuria reducing effect of Losartan on normotensive diabetic patients, as well as to determine the safety of Losartan.
Methodology: This longitudinal study was carried out on 33 diagnosed normotensive Diabetes Mellitus patients with micro albuminuria of either gender, aged 40-60 years, from out diabetic clinics of Rajshahi and Kushtia district of Bangladesh from July 2023 to June 2024. The baseline levels of Microalbuminuria were recorded, and patients were given 50 mg Losartan per day for 6 weeks. After 6 weeks, patients were reassessed for Microalbuminuria. During this procedure, 3 patients dropped out.
Results: Before Losartan therapy urinary albumin levels were µ ± SEM= 103± 0.37, and after Losartan therapy urinary albumin levels were µ ± SEM=79±.53. The result showed Losartan reduces Microalbumuria significantly. Dizziness developed in two patients and was managed.
Significance: The early treatment with Losartan in normotensive diabetic patients with Microalbuminuria will reduce or delay devotement of end-stage renal disease.

Keywords: Losartan, Microalbuminuria, Diabetic patients

References

1. Agha, A., Bashir, K. and Anwar, E. (2007) ‘Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus’, Nepal Med. Coll. J., 9(2), pp. 79-83. https://pubmed.ncbi.nlm.nih.gov/17899953/
2. AIHW (2024) Person—microalbumin level (measured), total micrograms per minute N[NNN].N. Australian Institute of Health and Welfare. Available at: https://meteor.aihw.gov.au/content/270336 (Accessed on: 13^th December 2024).
3. Akter, S., Rahman, M., Abe, S.K. and Sultana, P. (2014) ‘Prevalenc of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide suver’, Bulletin of the World Health Organization, 92(3), pp. 204-213. https://doi.org/10.2471/blt.13.128371
4. Andersen, S., Tarnow, L., Rossing, P., Hansen, B.V. and Parving, H.H. (2000) ‘Renoprotective effects of angiotensin II receptor blockade in type 1diabetic patients with diabetic nephropathy’, Kidney Int., 57(2), pp. 601-6. https://pubmed.ncbi.nlm.nih.gov/10652037/
5. Basi, S. and Lewis, J.B. (2006) ‘Microalbuminuria as a target to improve cardiovascular and renal outcomes’, Amer. J. Kidney Dis., 47(6), pp. 927-946. https://pubmed.ncbi.nlm.nih.gov/16731288/
6. Brenner, B.M., Cooper, M.E., de Zeeuw, D. et al. (2001) ‘Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy’, New Engl.  J. Med., 345(12), pp. 861-869. https://pubmed.ncbi.nlm.nih.gov/11565518/
7. Collins, A.J., Kasiske, B., Chen, S.C., et al. (2000) ‘Excerpts from United States Renal Data System 2000 annual data report: atlas of end-stage renal disease in the United States’, Amer. J. Kidney Dis., 36(6 Suppl. 2), pp. 163-176. https://pure.johnshopkins.edu/en/publications/excerpts-from-the-united-states-renal-data-system-2000-annual-dat-3/
8. Cowley, A.J., Wiens, B.L., Segal, R., et al. (2000) ‘Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy’, Qual. Life Res., 9(4), pp. 377-384. https://pubmed.ncbi.nlm.nih.gov/11131930/
9. Deswal, P. (2025) ‘A review of efficacy and safety of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapies compared to conventional treatment in patients with Retinal Vein Occlusion (RVO)’, International Journal of Technology, Health and Sustainability, 1(1), pp. 1-7. https://ijths.com/2025/09/28/a-review-of-efficacy-and-safety-of-anti-vascular-endothelial-growth-factor-anti-vegf-therapies-compared-to-conventional-treatment-in-patients-with-retinal-vein-occlusion-rvo/
10. Fischer. J. and Ganellin, C.R. (2006) Analogue-based drug discovery. John Wiley & Sons. https://onlinelibrary.wiley.com/doi/book/10.1002/3527608001
11. Hostetter, T.H. (2001) ‘Prevention of end-stage renal disease due to type 2 diabetes’, New Engl. J. Med., 345(12), pp. 910-912. https://doi.org/10.1056/nejm200109203451209
12. Jensen, J.S. (2007) ‘Microalbuminuria is a strong determinant for ischemic heart disease—also among non-diabetics’, Ugeskr Laeger, 169, pp. 485-7.
13. Lacourciere, Y., Belanger, A., Godin, C., et al. (2000) ‘Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy’, Kidney Int., 58(2), pp. 762-769. https://pubmed.ncbi.nlm.nih.gov/10916100/
14. Lozano, J.V., Llisterri, J.L., Aznar, J. and Redon, J. (2001) ‘Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics’, Nephrol Dial Transplant, 16 (Suppl. 1), pp. 85-89. https://pubmed.ncbi.nlm.nih.gov/11369830/
15. Okwori A.O., Agna M.A., Ofem O.A. (2025) ‘Fuzzy Logic Based Personalised Diet Recommendation Engine for Stroke Vulnerable Patients’, International Journal of Technology, Health and Sustainability, 2(1), pp. 6-16. https://ijths.com/2026/01/06/fuzzy-logic-based-personalised-diet-recommendation-engine-for-stroke-vulnerable-patients/
16. Parvanova, A., Chiurchiu, C., Ruggenenti, P. and Remuzzi, G. (2005) ‘Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade’, Expert Opin Pharmacother, 6(11), pp. 1931-42. https://doi.org/10.1517/14656566.6.11.1931
17. Remuzzi, G., Schieppati, A. and Ruggenenti, P. (2002) ‘Clinical practice. Nephropathy in patients with type 2 diabetes’, New Engl. J. Med., 346(15), pp. 1145-51. https://doi.org/10.1056/nejmcp011773
18. Rossing, P. (2006) ‘Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history’, Curr. Diab. Rep., 6(6), pp. 479-483. https://doi.org/10.1007/s11892-006-0083-y
19. Ruggenenti, P., Fassi, A., Ilieva, A.P., et al. (2004) ‘Preventing microalbuminuria in type 2 diabetes’, New Engl. J. Med., 351(19), pp. 1941-51. https://doi.org/10.1056/nejmoa042167
20. WHO (2004) The diabetes program 2004. World Health Organisation. Available at: https://www.who.int/diabetes/en/